Novo Nordisk submits obesity drug for FDA approval

Semaglutide will also be used as a treatment for obesity, according to Novo Nordisk's plan – the pharmaceutical giant has submitted an application to the FDA in the US.
Photo: Stine Tidsvilde
Photo: Stine Tidsvilde
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

Within the next six months, Novo Nordisk will find out whether its drug semaglutide can be used as a treatment for obesity, aside from its use as a drug against diabetes in US patients.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading